The SARS-CoV-2 pandemic impacts society in unseen ways, pushing biosafety practices in everyday situations, and with a strengthened public interest in containment and safety measures. At the same time biosafety professionals had to reorient themselves to cope with extraordinary situations, requiring creative solutions. Building on this dynamic, the EBSA 2022 Conference will be the meeting place where biosafety professionals can reconnect, share effective and practical approaches, and thereby accelerate Biosafety.
The training will focus on:
> the main approaches in gene therapy (using various gene vectors), with an attention paid on the biosafety aspects in research and development laboratories, as well as on the risk for the patient
> the viral vectors used frequently in current gene therapy project, with the aim to point out their respective benefits in term of efficacy and safety
Participants will have the opportunity to perform a team-work risk assessment on case studies corresponding to current clinical trials.